Buy PHENIBUT 250 mg/tab, 20/50 tablets online. Free worldwide shipping.
Brand: Obninsk chemical-pharmaceutical company, CJSC (Russia)
Drug form: Tablet
Manufacturers: Russia
Active substance: Aminophenylbutyric acid
Group: Other psychostimulants and nootropic drugs
Expiration date: 3 years
More about the drug in Russian
We accept all the major cards including Visa, Maestro, Master Card and other. All the transactions are 100% secure and backed by Stripe financial services. Read more about the service.
We undertake all fees for the delivery and currency exchange.
Feel free to contact us in case of any questions: manager@befitpharma.com
PHENIBUT 250 mg/tab, 20/50 tablets
Indications for use of Phenibut are:
Asthenic and anxiety-neurotic states; stuttering, tics and enuresis in children. Insomnia and nocturnal anxiety in the elderly; Meniere's disease, dizziness associated with dysfunctions of the vestibular analyzer of various origins; prevention of motion sickness in kinetosis; as part of complex therapy for alcohol withdrawal syndrome for the relief of psychosomatic and somatovegetative disorders.
Pharmacological properties
Pharmacodynamics:
Phenibut normalizes metabolic processes in the nerve cells of the brain. The active ingredient of the drug Phenibut (aminophenylbutyric acid hydrochloride) can be considered as a derivative of γ-amino-butyric acid (GABA) or as a derivative of β-phenylethylamine. Phenibut has nootropic activity, and as a GABA derivative, it has an anxiolytic (tranquilizing) effect. Does not affect choline and adrenergic receptors.
The drug reduces tension, anxiety, fear and improves sleep, therefore it is used to treat neuroses and before surgery. Phenibut lengthens and enhances the effect of hypnotics, narcotic, neuroleptic and antiparkinsonian drugs. Phenibut is devoid of anticonvulsant activity, lengthens the latent period of nystagmus and shortens its duration and severity. The drug reduces the manifestations of asthenia and vaso-vegetative symptoms, including headache, a feeling of heaviness in the head, sleep disturbance, irritability, emotional lability and increases mental performance. Psychological indicators (attention, memory, speed and accuracy of sensory-motor reactions) under the influence of the drug are improved, in contrast to the influence of tranquilizers. In patients with asthenia and in emotionally labile patients, from the very first days of therapy, subjective well-being improves, interest and initiative, and motivation for activity increase.
Pharmacokinetics:
Aminophenylbutyric acid is well absorbed after oral administration and penetrates into all body tissues, easily overcomes the blood-brain barrier. About 0.1% of the administered dose of the drug penetrates into the brain tissue, and to a much greater extent in young and old people. It is metabolized in the liver - 80-95%, to pharmacologically inactive metabolites. About 5% is excreted by the kidneys unchanged, partly with bile. With repeated admission, cumulation is not observed.